Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Intarcia Therapeutics, Inc
Hayward, California, United States
Start Date
February 1, 2013
Primary Completion Date
July 1, 2014
Completion Date
July 1, 2014
Last Updated
December 25, 2012
ITCA 650 60 mcg/day
DRUG
sitagliptin
DRUG
Lead Sponsor
Intarcia Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06671587